1. Requirements for DXA for the management of osteoporosis in Europe;Kanis;Osteoporos Int,2005
2. Treatment of postmenopausal osteoporosis;Delmas;Lancet,2002
3. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis;Stevenson;Health Technol Assess,2005
4. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women;National Institute for Clinical Excellence,2005
5. Appraisal consultation document. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women;National Institute for Health and Clinical Excellence,2007